Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Autor: Jocelyn M. Weiss, Shih-Chen Chang, Robert L. Grubb, Arthur Schatzkin, Michael F. Leitzmann, Gerald L. Andriole, Jiyoung Ahn, Kim N. Danforth, Ann W. Hsing, Wen-Yi Huang, Demetrius Albanes
Rok vydání: 2008
Předmět:
Male
Oncology
Cancer Research
Time Factors
Prostate volume
Body Mass Index
Prostate cancer
0302 clinical medicine
Risk Factors
Prostate
Surveys and Questionnaires
Cancer screening
Odds Ratio
Mass Screening
Multicenter Studies as Topic
Medicine
Prospective Studies
030212 general & internal medicine
Digital Rectal Examination
Randomized Controlled Trials as Topic
Incidence
Diabetes
Middle Aged
Tumor Burden
3. Good health
Prostate-specific antigen
medicine.anatomical_structure
030220 oncology & carcinogenesis
Screening
Prostate specific antigen
PCA3
medicine.medical_specialty
Motor Activity
Article
03 medical and health sciences
Internal medicine
Diabetes mellitus
Confidence Intervals
Diabetes Mellitus
Humans
Mass screening
Aged
business.industry
Prostatic Neoplasms
Cancer
Prostate-Specific Antigen
medicine.disease
United States
Epidemiologic Methods
business
Follow-Up Studies
Zdroj: Cancer causes & control : CCC
ISSN: 1573-7225
0957-5243
DOI: 10.1007/s10552-008-9198-6
Popis: Objective A history of diabetes has been fairly consistently related to a reduced prostate cancer risk, but previous investigations have not always addressed whether the relation with diabetes varies by prostate cancer aggressiveness or the association between diabetes and prostate cancer is modified by physical activity level and body mass, variables closely related to glucose metabolism. Methods We prospectively examined the diabetes–prostate cancer risk relationship among 33,088 men in the screening arm of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Results During 8.9 years follow-up, we ascertained 2,058 incident prostate cancer cases. Diabetes history was related to decreased risk of total prostate cancer (RR = 0.80, 95% CI = 0.68–0.95). The apparent protection afforded by diabetes was primarily due to the inverse relation with non-aggressive disease (i.e., the combination of low grade (Gleason sum
Databáze: OpenAIRE
Externí odkaz: